(Total Views: 723)
Posted On: 02/02/2022 12:37:39 PM
Post# of 155790
Lots of options/possibilities for financing:
Combining the rights of Regnum and CYDY into a new entity is something that just occurred to me, or maybe buying back all the rights from Regnum, or buying out the CYDY HIV rights altogether for some lump sum and reduced royalties - $100-$200M and 10% instead of 50%?
Straight private placement - someone buys say 10% for 80M shares for ~$50M?
Partner with equity interest: they would give an upfront of cash for rights to NASH, say $50M, and also invest $50M to buy 10% of equity?
Buyout
Who knows - just throwing possible things out there. Sorry for the diversion.
Hopefully we find out soon how we will finance things going forward.
Best case would be outstanding results and raise money ourselves at a higher price as a secondary. But a partner (BP), new financier (PIPE), new entity with HIV spinout, may be other possible options to bring in much needed cash for further leronlimab development until we get some sales coming in.
Combining the rights of Regnum and CYDY into a new entity is something that just occurred to me, or maybe buying back all the rights from Regnum, or buying out the CYDY HIV rights altogether for some lump sum and reduced royalties - $100-$200M and 10% instead of 50%?
Straight private placement - someone buys say 10% for 80M shares for ~$50M?
Partner with equity interest: they would give an upfront of cash for rights to NASH, say $50M, and also invest $50M to buy 10% of equity?
Buyout
Who knows - just throwing possible things out there. Sorry for the diversion.
Hopefully we find out soon how we will finance things going forward.
Best case would be outstanding results and raise money ourselves at a higher price as a secondary. But a partner (BP), new financier (PIPE), new entity with HIV spinout, may be other possible options to bring in much needed cash for further leronlimab development until we get some sales coming in.
(0)
(0)
